Fertility and Sterility
Volume 89, Issue 5 , Pages 1234-1239 , May 2008

GnRH antagonists may affect endometrial receptivity

  • Beth W. Rackow, M.D.
    • ,
  • Harvey J. Kliman, M.D., Ph.D.
    • ,
  • Hugh S. Taylor, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests: Hugh S. Taylor, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, P.O. Box 208063, New Haven, CT 06520-8063 (FAX: 203-785-7134).

Received 16 April 2007 ,Revised 23 April 2007 ,Accepted 23 April 2007.

References 

  1. Huisman GJ, Fauser BC, Eijkemans MJ, Pieters MH. Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. Fertil Steril. 2000;73:117–122
  2. Schoolcraft WB, Gardner DK. Blastocyst versus day 2 or 3 transfer. Semin Reprod Med. 2001;19:259–268
  3. Levi AJ, Drews MR, Bergh PA, Miller BT, Scott RT. Controlled ovarian hyperstimulation does not adversely affect endometrial receptivity in in vitro fertilization cycles. Fertil Steril. 2001;76:670–674
  4. Pattinson HA, Greene CA, Fleetham J, Anderson-Sykes SJ. Exogenous control of the cycle simplifies thawed embryo transfer and results in a pregnancy rate similar to that for natural cycles. Fertil Steril. 1992;58:627–629
  5. Pellicer A, Valbuena D, Cano F, Remohi J, Simon C. Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertil Steril. 1996;65:1190–1195
  6. Queenan JT, Veeck LL, Seltman HJ, Muasher SJ. Transfer of cryopreserved-thawed pre-embryos in a natural cycle or a programmed cycle with exogenous hormonal replacement yields similar pregnancy results. Fertil Steril. 1994;62:545–550
  7. Simon C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Remohi J, et al. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil Steril. 1998;70:234–239
  8. Murdoch WJ. Immunolocalization of a gonadotropin-releasing hormone receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res. 1995;282:527–529
  9. Popovici RM, Kao LC, Giudice LC. Discovery of new inducible genes in in vitro decidualized human endometrial stromal cells using microarray technology. Endocrinology. 2000;141:3510–3513
  10. Shemesh M. Actions of gonadotrophins on the uterus. Reproduction. 2001;121:835–842
  11. Check JH, Choe JK, Katsoff D, Summers-Chase D, Wilson C. Controlled ovarian hyperstimulation adversely affects implantation following in vitro fertilization–embryo transfer. J Assist Reprod Genet. 1999;16:416–420
  12. Simon C, Cano F, Valbuena D, Remohi J, Pellicer A. Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod. 1995;10:2432–2437
  13. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update. 2003;9:515–522
  14. Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. 2004;15:84–90
  15. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002;78:1025–1029
  16. Simon C, Oberye J, Bellver J, Vidal C, Bosch E, Horcajadas JA, et al. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod. 2005;20:3318–3327
  17. Ganirelix Dose-Finding Study Group . A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 1998;13:3023–3031
  18. Williams RS, Hillard JB, De Vane G, Yeko T, Kipersztok S, Rhoton-Vlasak A, et al. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. Am J Obstet Gynecol. 2004;191:648–651discussion 651–3
  19. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38–45
  20. Seelig AS, Al-Hasani S, Katalinic A, Schopper B, Sturm R, Diedrich K, et al. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril. 2002;77:472–475
  21. Tarlatzis BC, Bili HN. Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential nonassisted reproductive technology applications. Curr Opin Obstet Gynecol. 2003;15:259–264
  22. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2001;4:CD001750
  23. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol. 2004;115(Suppl 1):S44–S56
  24. Diedrich K, Ludwig M, Felberbaum RE. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization. Semin Reprod Med. 2001;19:213–220
  25. Gordon K. Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity. Ann N Y Acad Sci. 2001;943:49–54
  26. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2000;15:1211–1216
  27. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 2001;265:175–182
  28. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update. 2002;8:279–290
  29. Taylor HS. The role of HOX genes in human implantation. Hum Reprod Update. 2000;6:75–79
  30. Taylor HS, Arici A, Olive D, Igarashi P. HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. J Clin Invest. 1998;101:1379–1384
  31. Block K, Kardana A, Igarashi P, Taylor HS. In utero diethylstilbestrol (DES) exposure alters HOX gene expression in the developing mullerian system. FASEB J. 2000;14:1101–1108
  32. Taylor HS, Bagot C, Kardana A, Olive D, Arici A. HOX gene expression is altered in the endometrium of women with endometriosis. Hum Reprod. 1999;14:1328–1331
  33. Taylor HS, Vanden Heuvel GB, Igarashi P. A conserved HOX axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the HOXA cluster genes. Biol Reprod. 1997;57:1338–1345
  34. Bagot CN, Kliman HJ, Taylor HS. Maternal HOXA10 is required for pinopod formation in the development of mouse uterine receptivity to embryo implantation. Dev Dyn. 2001;222:538–544
  35. Bagot CN, Troy PJ, Taylor HS. Alteration of maternal HOXA10 expression by in vivo gene transfection affects implantation. Gene Ther. 2000;7:1378–1384
  36. Taylor HS, Daftary GS, Selam B. Endometrial HOXA10 expression after controlled ovarian hyperstimulation with recombinant follicle-stimulating hormone. Fertil Steril. 2003;80(Suppl 2):839–843
  37. Satokata I, Benson G, Maas R. Sexually dimorphic sterility phenotypes in HOXA10-deficient mice. Nature. 1995;374:460–463
  38. Sarno JL, Kliman HJ, Taylor HS. HOXA10, PBX2, and MEIS1 protein expression in the human endometrium: formation of multimeric complexes on HOXA10 target genes. J Clin Endocrinol Metab. 2005;90:522–528
  39. Daftary GS, Taylor HS. Pleiotropic effects of HOXA10 on the functional development of peri-implantation endometrium. Mol Reprod Dev. 2004;67:8–14
  40. Daftary GS, Troy PJ, Bagot CN, Young SL, Taylor HS. Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. Mol Endocrinol. 2002;16:571–579
  41. Kim JJ, Buzzio OL, Li S, Lu Z. Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biol Reprod. 2005;73:833–839
  42. Troy PJ, Daftary GS, Bagot CN, Taylor HS. Transcriptional repression of peri-implantation EMX2 expression in mammalian reproduction by HOXA10. Mol Cell Biol. 2003;23:1–13
  43. Cermik D, Selam B, Taylor HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:238–243
  44. Daftary GS, Taylor HS. Hydrosalpinx fluid diminishes endometrial cell HOXA10 expression. Fertil Steril. 2002;78:577–580
  45. Noyes RW, Hertig AF, Rock J. Dating the endometrial biopsy. Fertil Steril. 1950;1:3–25
  46. Lessey BA, Castelbaum AJ, Sawin SW, Buck CA, Schinnar R, Bilker W, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab. 1994;79:643–649
  47. Sharpe-Timms KL, Ricke EA, Piva M, Horowitz GM. Differential expression and localization of de-novo synthesized endometriotic haptoglobin in endometrium and endometriotic lesions. Hum Reprod. 2000;15:2180–2185
  48. Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online. 2003;6:432–438

PII: S0015-0282(07)01015-1

doi: 10.1016/j.fertnstert.2007.04.060

Fertility and Sterility
Volume 89, Issue 5 , Pages 1234-1239 , May 2008

Article Tools

* Image Usage & Resolution